Literature DB >> 36255405

Spatial modeling reveals nuclear phosphorylation and subcellular shuttling of YAP upon drug-induced liver injury.

Sven Sahle1, Kai Breuhahn2, Lilija Wehling2,1, Liam Keegan1, Paula Fernández-Palanca2,3,4, Reham Hassan5,6, Ahmed Ghallab5,6, Jennifer Schmitt2, Yingyue Tang2, Maxime Le Marois2, Stephanie Roessler2, Peter Schirmacher2, Ursula Kummer1, Jan G Hengstler5.   

Abstract

The Hippo signaling pathway controls cell proliferation and tissue regeneration via its transcriptional effectors yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ). The canonical pathway topology is characterized by sequential phosphorylation of kinases in the cytoplasm that defines the subcellular localization of YAP and TAZ. However, the molecular mechanisms controlling the nuclear/cytoplasmic shuttling dynamics of both factors under physiological and tissue-damaging conditions are poorly understood. By implementing experimental in vitro data, partial differential equation modeling, as well as automated image analysis, we demonstrate that nuclear phosphorylation contributes to differences between YAP and TAZ localization in the nucleus and cytoplasm. Treatment of hepatocyte-derived cells with hepatotoxic acetaminophen (APAP) induces a biphasic protein phosphorylation eventually leading to nuclear protein enrichment of YAP but not TAZ. APAP-dependent regulation of nuclear/cytoplasmic YAP shuttling is not an unspecific cellular response but relies on the sequential induction of reactive oxygen species (ROS), RAC-alpha serine/threonine-protein kinase (AKT, synonym: protein kinase B), as well as elevated nuclear interaction between YAP and AKT. Mouse experiments confirm this sequence of events illustrated by the expression of ROS-, AKT-, and YAP-specific gene signatures upon APAP administration. In summary, our data illustrate the importance of nuclear processes in the regulation of Hippo pathway activity. YAP and TAZ exhibit different shuttling dynamics, which explains distinct cellular responses of both factors under physiological and tissue-damaging conditions.
© 2022, Wehling et al.

Entities:  

Keywords:  DILI; Hippo pathway; TAZ; acetaminophen; computational biology; human; medicine; mouse; partial differential equations; systems biology

Mesh:

Substances:

Year:  2022        PMID: 36255405      PMCID: PMC9578710          DOI: 10.7554/eLife.78540

Source DB:  PubMed          Journal:  Elife        ISSN: 2050-084X            Impact factor:   8.713


  56 in total

Review 1.  The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal.

Authors:  Bin Zhao; Karen Tumaneng; Kun-Liang Guan
Journal:  Nat Cell Biol       Date:  2011-08-01       Impact factor: 28.824

2.  Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis.

Authors:  Xiaobo Wang; Ze Zheng; Jorge Matias Caviglia; Kathleen E Corey; Tina M Herfel; Bishuang Cai; Ricard Masia; Raymond T Chung; Jay H Lefkowitch; Robert F Schwabe; Ira Tabas
Journal:  Cell Metab       Date:  2016-10-27       Impact factor: 27.287

3.  Exploring the influence of cytosolic and membrane FAK activation on YAP/TAZ nuclear translocation.

Authors:  Kerbaï Saïd Eroumé; Rachel Cavill; Katerina Staňková; Jan de Boer; Aurélie Carlier
Journal:  Biophys J       Date:  2021-09-10       Impact factor: 3.699

Review 4.  YAP/TAZ as mechanosensors and mechanotransducers in regulating organ size and tumor growth.

Authors:  Boon Chuan Low; Catherine Qiurong Pan; G V Shivashankar; Alexander Bershadsky; Marius Sudol; Michael Sheetz
Journal:  FEBS Lett       Date:  2014-04-18       Impact factor: 4.124

5.  Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control.

Authors:  Bin Zhao; Xiaomu Wei; Weiquan Li; Ryan S Udan; Qian Yang; Joungmok Kim; Joe Xie; Tsuneo Ikenoue; Jindan Yu; Li Li; Pan Zheng; Keqiang Ye; Arul Chinnaiyan; Georg Halder; Zhi-Chun Lai; Kun-Liang Guan
Journal:  Genes Dev       Date:  2007-11-01       Impact factor: 11.361

6.  A spatial model of YAP/TAZ signaling reveals how stiffness, dimensionality, and shape contribute to emergent outcomes.

Authors:  Kiersten Elizabeth Scott; Stephanie I Fraley; Padmini Rangamani
Journal:  Proc Natl Acad Sci U S A       Date:  2021-05-14       Impact factor: 11.205

7.  Hippo pathway coactivators Yap and Taz are required to coordinate mammalian liver regeneration.

Authors:  Li Lu; Milton J Finegold; Randy L Johnson
Journal:  Exp Mol Med       Date:  2018-01-05       Impact factor: 8.718

8.  Transcriptomic Cross-Species Analysis of Chronic Liver Disease Reveals Consistent Regulation Between Humans and Mice.

Authors:  Christian H Holland; Ricardo O Ramirez Flores; Maiju Myllys; Reham Hassan; Karolina Edlund; Ute Hofmann; Rosemarie Marchan; Cristina Cadenas; Jörg Reinders; Stefan Hoehme; Abdel-Latif Seddek; Steven Dooley; Verena Keitel; Patricio Godoy; Brigitte Begher-Tibbe; Christian Trautwein; Christian Rupp; Sebastian Mueller; Thomas Longerich; Jan G Hengstler; Julio Saez-Rodriguez; Ahmed Ghallab
Journal:  Hepatol Commun       Date:  2021-08-28

9.  A Model for the Hippo Pathway in the Drosophila Wing Disc.

Authors:  Jia Gou; Lin Lin; Hans G Othmer
Journal:  Biophys J       Date:  2018-07-11       Impact factor: 4.033

Review 10.  New insights into YAP/TAZ nucleo-cytoplasmic shuttling: new cancer therapeutic opportunities?

Authors:  Michal Shreberk-Shaked; Moshe Oren
Journal:  Mol Oncol       Date:  2019-05-17       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.